The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.
Like tuberculosis and other diseases, drug resistant HIV strains emerge in part because a person doesn’t take the proper dose of drugs at the right time every day. In poor regions like...
Source: Science - The Huffington Post - December 6, 2016 Category: Science Source Type: news
Tanzania: Muhimbili National Hospital Plans Free Hepatitis Treatment
[Daily News] Muhimbili National Hospital (MNH) plans to establish a diagnosis of hepatitis B virus and offer free treatment with Tenofovir medication to patients for five years effective next month. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 29, 2016 Category: African Health Source Type: news
Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news
Vemlidy Tablets (Tenofovir Alafenamide) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 23, 2016 Category: Drugs & Pharmacology Source Type: news
CHMP Backs Tenofovir Alafenamide (Vemlidy) for Chronic Hep B CHMP Backs Tenofovir Alafenamide (Vemlidy) for Chronic Hep B
Vemlidy has efficacy similar to that of tenofovir disoproxil (Viread), with fewer bone and renal side effects.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 11, 2016 Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news
FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
Once-daily Vemlidy has similar efficacy to tenofovir disoproxil (Viread) with fewer bone and renal side effects, the company says.FDA Approvals (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 11, 2016 Category: Respiratory Medicine Tags: Gastroenterology News Source Type: news
Novel Tenofovir Drug OK'd for Hepatitis B
(MedPage Today) -- Vemlidy approved for chronic HBV infection with compensated liver disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 10, 2016 Category: American Health Source Type: news
FDA Approves Gilead ’s Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy ® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 10, 2016 Category: Drugs & Pharmacology Source Type: news
Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil)
This new medicine evidence summary reviewed 4 randomised trials of Truvada (emtricitabine/tenofovir disoproxil 200 mg/245 mg) for pre-exposure prophylaxis (PrEP) of HIV in either HIV-negative men or transgender women who have sex with men, or HIV-negative individuals in a heterosexual partnership with a person already infected with HIV. In these trials, Truvada reduced the relative risk of acquiring HIV infection by between 44% and 86% compared with placebo or no prophylaxis, which is equivalent to approximate numbers needed to treat of between 13 and 68 per year. In all trials, Truvada was given in addition to a comprehen...
Source: Current Awareness Service for Health (CASH) - October 6, 2016 Category: Consumer Health News Source Type: news
New Tenofovir Formulation Provides Safer Hepatitis B Treatment New Tenofovir Formulation Provides Safer Hepatitis B Treatment
A new prodrug formulation, tenofovir alafenamide, effectively treats chronic hepatitis B virus (HBV) infection with fewer bone and renal adverse effects than tenofovir disoproxil fumarate, according to two noninferiority trials.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 1, 2016 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
When investigators reviewed Emtricitabine/tenofovir alafenamide in HIV infection, they found that partly no data were available, and partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group, they conclude. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 18, 2016 Category: Science Source Type: news
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
(Institute for Quality and Efficiency in Health Care) Partly no data were available, partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2016 Category: Global & Universal Source Type: news
Entecavir/Tenofovir Therapy in Drug Resistant Chronic HBV Entecavir/Tenofovir Therapy in Drug Resistant Chronic HBV
This study evaluated the antiviral efficacy and safety of entecavir plus tenofovir combination therapy in multidrug-resistant chronic hepatitis B patients.Liver International (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 16, 2016 Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news
[In Depth] Vaginal microbiome affects HIV risk
South African teen girls and young women have astonishingly high rates of HIV infection, and researchers for years have suspected that there might be biological factors making them unusually susceptible to infection. New studies presented at the International AIDS Conference being held in Durban, South Africa—located in KwaZulu-Natal province, the hardest hit region in the country—suggest a possible culprit, Prevotella bivia, a bacterium found in the vagina that causes inflammation. The close examination of the vaginal microbiome found a second bacterium, Gardnerella, may help explain why a microbicide gel that contain...
Source: ScienceNOW - July 21, 2016 Category: Science Authors: Jon Cohen Tags: Infectious Disease Source Type: news
What ’s keeping PrEP under wraps
< p >
PrEP, or pre-exposure prophylaxis, is a safe and effective medication that can prevent at-risk patients from contracting HIV, yet the treatment is not widely known by physicians or the patient base that could benefit most from it. Learn what HIV experts say about the treatment and the obstacles to integrating it into primary care practice. < /p > < p > < strong > Getting the word out < /strong > < /p > < p >
PrEP reaches a small proportion of the Americans who could benefit from it, experts said at an education session by the AMA LGBT Advisory Committee during the < a href= " http://www.ama-assn.org/sub/meeting/i...
Source: AMA Wire - July 19, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news
